Agenus to receive $25 million milestone payment from bristol myers squibb for tigit-cd96 bispecific program

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in developing novel immunological agents to treat various cancers, today announced it has triggered the second development milestone payment under its global licensing agreement with bristol myers squibb for bms-986442, an fc-enhanced bispecific tigit antibody. agenus will receive a $25 million cash payment from bristol myers squibb with the dosing of the first patient in the phase 2 dose expansion portion of the.
AGEN Ratings Summary
AGEN Quant Ranking